The human body's liver has the best capacity for regeneration. But a variety of assaults, including as viral infections, drug or alcohol addiction, and metabolic stress, can result in chronic inflammation and fibrosis, which then results in irreversible liver damage. Liver illnesses continue to be a major cause of death globally despite improvements in surgery and pharmaceutical therapies. Cell therapy for liver illness has become a promising regenerative therapy to address the lack of donor liver organs for orthotopic liver transplantation. Primary hepatocytes or functional hepatocytes produced by reprogramming Induced Pluripotent Stem Cells (IPSC) are examples of sources. Hematopoietic Stem Cells (HSCs), Mesenchymal Stromal Cells (MSCs), Endothelial Progenitor Cells (EPCs), as well as adult and foetal hepatic progenitor cells, have all been used as stem cell transplants to promote regeneration. Due to their autologous character, simplicity of isolation, and ability to be preserved in cryo, HSCs, which are often identified by the expression of CD34 and CD133, and MSCs, which are identified by the expression of CD105, CD73, and CD90, are desirable sources . The study focuses on the application of HSCs from bone marrow for liver regeneration and provides proof of continuous interactions between the hematopoietic and hepatic systems. This connection is established during embryogenesis, when the foetal liver develops as the junction between the two systems, bringing together cells from separate cellular origins (mesoderm and endoderm) in one organ. A further indication that this link between the two systems is still present is the fact that the adult liver continues to be one of the few sites for extra medullary hematopoiesis, albeit in a diseased manner.
